about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

FTC’s M&A crack­down; NASH drug gets thumbs down; FDA OKs top­i­cal gene ther­a­py; Com­pa­ny ex­its frus­trate rare dis­ease ...

Last year
Weekly

Ab­b­Vie, Gen­mab land FDA OK for CD3xCD20 bis­pe­cif­ic, catch­ing up with Roche

Last year
FDA+

Ca­balet­ta lands $84M from stock sale af­ter FDA clears INDs for CD19 CAR-T in au­toim­mune dis­eases

Last year
Financing

Roche touts PhII win for BTK in­hibitor in mul­ti­ple scle­ro­sis as PhI­II show­down with Sanofi, Mer­ck KGaA, No­var­tis ...

2 years ago
R&D

Gilead woos Cindy Perettie from Roche to lead Kite af­ter Christi Shaw de­parts

2 years ago
People
Cell/Gene Tx

BioX­cel touts healthy vol­un­teer da­ta for neu­ro ther­a­py; Io­n­is, Chi­nook part­ner on rare kid­ney dis­ease

2 years ago
News Briefing

FTC sues to block $28B Am­gen-Hori­zon deal, in move that will send shock­waves through bio­phar­ma M&A

3 years ago
Deals

Still un­der clin­i­cal hold, Ful­crum locks in sea­soned com­mer­cial leader as CEO

3 years ago
People
R&D

Athenex files for bank­rupt­cy to pave way for fire­sale of pro­grams, end­ing 20-year run

3 years ago
People

FDA ad­vi­sors back Sarep­ta's gene ther­a­py; Lay­offs, big and small; Gilead, So­bi fu­el M&A fire; End­points 100; and more

3 years ago
Weekly

In­novent show­cas­es topline PhII win for high-dose obe­si­ty drug in Chi­na

3 years ago
R&D
China

Ex­clu­sive: Af­ter win­ning le­gal bat­tle, for­mer Phase­Bio in­vestor finds US buy­er for its PhI­II drug to re­verse Bril­in­ta

3 years ago
Deals

Gos­samer lays off 25% of em­ploy­ees, cuts all pro­grams ex­cept PAH drug

3 years ago
People

So­bi swoops in with $1.7B buy­out for a biotech with an ap­proved JAK in­hibitor, but low on cash

3 years ago
Deals

Bay­er fol­lows No­var­tis' foot­steps in ink­ing ra­dio­phar­ma pact with Bi­cy­cle, pay­ing $45M cash up­front

3 years ago
Deals

Roche hands Chi­nese biotech $70M for HER2 drug that can go to the brain

3 years ago
Deals
China

No­vavax lays off hun­dreds of em­ploy­ees as new CEO goes in­to res­cue mode

3 years ago
People
Coronavirus

Af­ter Ru­bius col­lapse and brief stop at Flag­ship start­up, Pablo Cagnoni finds new start at In­cyte

3 years ago
People
R&D

Eli Lil­ly's Alzheimer’s win; Astel­las joins buy­er­s' club with $5.9B deal; $540M biotech IPO; His­toric RSV vac­cine ...

3 years ago
Weekly

Alessan­dro Ri­va takes over Trans­gene as As­traZeneca walks away from on­colyt­ic virus pact

3 years ago
People
Deals

Roche dou­bles down on organoids, hu­man mod­el sys­tems with new re­search in­sti­tute

3 years ago
R&D
Discovery

‘Un­be­liev­ably im­por­tant mo­ment’: Sarep­ta clears the air on man­u­fac­tur­ing, pay­ers ahead of gene ther­a­py ad­comm

3 years ago
Cell/Gene Tx
FDA+

In­cyte cuts fi­nal tri­al for PI3K drug more than a year af­ter yank­ing ac­cel­er­at­ed ap­proval fil­ing

3 years ago
R&D

IMV finds 'breath­ing room' to look for deals or in­vest­ments, will not en­roll new pa­tients in PhI­Ib can­cer vac­cine ...

3 years ago
R&D
First page Previous page 11121314151617 Next page Last page
A service from the Financial Times